Try our Advanced Search for more refined results
Life Sciences - September, 2006
118 articles
- Law Firm Profile: Merchant & Gould
- Report: FDA Should Improve Defibrillator Communication
- Baxter Gets Surprise Setback In Japanese Ultane Ruling
- Sanofi-Aventis Scores Trademark Victory
- King & Spalding Lures In IP Prosecution Team
- Lawsuit Over High-Tech Braces Settled With $20M Deal
- SeraCare Shareholders Denied Bid To Slow Proceedings
- Barr Launches Generic Actiq
- Jury Deadlocks In Wyeth Hormone Replacement Trial
- Encysive Pharmaceuticals Hit With Securities Suit
- European Court Sides With Glaxo In Dual Pricing Case
- Merck Scores Second Win In Vioxx Onslaught
- Barr Challenges Savient's Oxandrin Patents
- J&J Sues Abbott, Boston Scientific For Over $5.5B
- Drug Makers Toss Authorized Generic Plan
- As Vioxx Deadline Looms, Merck Faces More Suits
- EU Regulator To Re-Examine Safety Of Common Drugs
- Hospital Stole Trade Secrets, Biotech Firm Charges
- Federal Circuit Upholds Dietary Supplement Rulings
- Novartis' Indian Patent Challenge Could Harm: MSF
- New Jersey Hospitals Present Unique Outlier Cases
- Study Finds FDA Falling Short of Drug Safety Expectations
- FDA Plans Studies Of On-The-Market Medications
- Schwarzenegger Kills Universal Health Care Bill
- Merck Lawyers Can Dig Through Juror's Personal Records
- Guidant Sues St. Jude Over Salespeople Recruitment
- Male Enhancement Maker Charged With Fraud
- Appeals Court Upholds Dismissal Of Enzo Fraud Claim
- Cytyc Reaffirms Offer For Vision Systems
- Doctors Bring Class Action Against Health Insurers
- Merck Appeals $26M Jury Verdict In First Vioxx Case
- Congress Pens Deal To Allow Canada Drug Imports
- SeraCare Modifies Chapter 11 Plan Amid Rival Bids
- Connetics Hit With Shareholder Lawsuit Over Failed Drug
- Federal Circuit Rules In Scantibodies' Favor
- Senate Battle Lies Ahead For FDA Nominee
- Judge Rules For Sanofi, Bristol-Myers In Plavix Case
- Datasci Settles Patent Litigation Against Datalabs
- Corporate America More Gay Friendly: Study
- Fueled By IP, U.S. Still Biotech Leader: Study
- GlaxoSmithKline Royalties Come Under Scrutiny
- Forest Executives Win Battle Against Shareholders
- Takeda Wins Attorneys Fees In Patent Suit
- AMS Health Sciences Settles Ephedra Suit
- Messy Health Care Merger To End Up In Court
- Judge Orders ImClone's Scientists Off Patent
- Enzo Settles DNA Patent Dispute
- Antitrust Fears Raised Over Potential Rite Aid Merger
- Pfizer Not Happy With Former Executive's Book
- Appeals Court Vacates Securities Class Action Decision
- 2nd Van Der Moolen Trader Acquitted Of Front-Running
- Wyeth Wins First Hormone Replacement Therapy Case
- In Win For Barr, Court Denies Tamoxifen Rehearing
- Guidant Buries One Hatchet In Defibrillator Fallout
- Bristol-Myers Begs Court To Preserve Plavix Injunction
- Clotting Data Prompts FDA To Promise Stent Review
- Execs Sentenced For Marketing Unapproved Devices
- Concessions Mark Solvay Settlement
- Australia Bids To Bolster Generic Drug Industry
- Baker Donelson Nabs White House Bigwig
- Acambis Says Willing To Settle In Patent Fight
- Cadwalader Nabs Morgan Lewis Antitrust Partner
- FDA Panel Shoots Down Oscient Request
- Mixed Victory For Pfizer In Dutch Lipitor Battle
- Battle Between Medical Device Makers Continues
- Biopure Escapes Damages In SEC Suit, GC Doesn't
- FDA Whistleblower Blasts New Merck Painkiller
- SeraCare Loses Control Of Its Chapter 11 Case
- Cross Country Healthcare Settles California Wage Suit
- Companies Battle Over Bone Cleaning Technology
- Stryker Plays Down DOJ Probe
- Amgen's Preemptive Strike Survives Motion To Dismiss
- Jury Mulls Evidence In Wyeth Premarin Trial
- The Impact Of Laboratory Corp. V. Metabolite On The Question Of Patentable Subject Matter
- Judge Bounces Derivative Suit Against Cell Therapeutics
- Bristol-Myers Head Fired Amid Plavix Debacle
- Amid Slump In Federal Litigation, Some Buck Trend
- FDA Concerned With Side Effect of Oscient Drug
- Pharmacists' Suit Over Morning-After Pill To Proceed
- Scrutiny Of Deals Jumped In 2005: FTC Report
- Whistleblower Case v. Pfizer Dismissed
- Jury Hands Innogenetics $7M In Damages
- SEC Hits Valeant With Multi-Pronged Probe
- DOJ Joins Whistleblower Suit Against Merck Affiliate
- Glaxo Agrees To $3.4B Settlement
- FDA Advisors Question Mercury Fillings Report
- PTO Strikes Down Ariad's Patent
- Pfizer Faces New Personal-Injury Suits Over Lipitor
- Barr Tries To Cut Generic Market By Entering It
- DEA Wants To Change Rules For Schedule II Drugs
- Law Firm's Investigation Finds Merck Innocent
- Howrey Adds Three Experts To Brussels Office
- Medical Method Patents
- Apotex Appeals Plavix Injunction To Federal Circuit
- Trial Date Set For NatWest Three
- Acambis Gets Boost With Smallpox Vaccine Ruling
- Fulbright Raids Sonnenschein To Expand Health Care Group
- J&J To Cough Up Millions More In Patent Case
- Medtronic Settles With Gyrus In Financial Draw
- GlaxoSmithKline Scores Parallel Trade Victory
- Novartis Sues To Protect Market For Epilepsy Drug
- Federal Circuit Hits J&J Unit With One-Two Punch
- California Governor Will Nix Health Care Bill
- Biotech Companies Settle Animal Cloning Patent Suit
- Roche Wants New Ruling On Tarceva
- Abbott Defeated In HCV Patent Feud
- FDA Hits Snooze Button on Neurocrine's Sleep Drug
- Hunton & Williams Acquires L.A. Trial Boutique
- Judge Denies Apotex Bid For Stay On Injunction
- Class Action Against Pharmaceutical Co. Dismissed
- Biotech Companies Settle Secretive Patent Suit
- FDA Rejects Sanofi-Aventis Drug Application
- Pfizer Wins Another Battle In Norvasc War
- Arnold & Porter Ranked #1 In Antitrust Litigation
- Compounded Medicines Legal, Federal Judge Rules
- Judge Refuses To Review Amgen Case
- Fish & Richardson Ranked #1 In Patent Litigation
- Court Grants Injunction Barring Generic Plavix